REFERENCES
1. Odame I. Developing a Global Agenda for Sickle Cell Disease. Report
of an International Symposium and Workshop in Cotonou, Republic of
Benin. Am J Prev Med. 2010;38:106.
2. Diallo DA, Guindo A. Sickle cell disease in sub-Saharan Africa:
stakes and strategies for control of the disease. Curr Opin Hematol.
2014;21:210-214.
3. Smart LR, Hernandez AG, Ware RE. Sickle cell disease: translating
clinical care to low- resource countries through international research
collaborations. Semin Hematol. 2018;55:102-112.
4. Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell
disease in Africa: a neglected cause of early childhood mortality. Am J
Prev Med. 2011;41:398-405.
5. Adewoyin AS. Management of sickle cell disease: a review for
physician education in Nigeria (sub-Saharan Africa). Anemia.
2015;10:1155-1498.
6. Mohammed CR, Annick G, Gilbert A, Roselyn A, Chantal D, Stephani G,
Eusebe A. Effect of a comprehensive clinical care program on disease
course in severely ill children with sickle cell anemia in a sub-Saharan
African setting. Blood. 2003;102:834-838.
7. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle
cell disease. Blood. 2004;103:4023-4027.
8. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell
disease– Life expectancy and risk factors for early death. N Engl J
Med.1994;330:1639-1644.
9. Mulumba LL, Wilson L. Sickle cell disease among children in Africa:
an integrative literature review and global recommendations. Int J
Africa Nurs Sci. 2015;3:56-64.
10. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden
of sickle cell anaemia in children under Five, 2010-2050: modelling
based on demographics, excess mortality, and interventions. PLoS Med.
2013;10:1001484.
11. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young
children with sickle-cell anaemia: a multicentre, randomised, controlled
trial (BABY HUG). Lancet. 2011;377:1663-1672.
12. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year
pilot trial of hydroxyurea in very young children with sickle-cell
anemia. J Pediatr. 2001;139:790-
796.
13. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the
frequency of painful crises in sickle cell anemia. N Engl J Med.
2002;332:1317-1322.
14. Rana S, Houston PE, Wang WC, et al. Hydroxyurea and growth in young
children with sickle cell disease. Pediatrics. 2014;134:465-472.
15. Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell
disease: a systematic review for efficacy and toxicity in children.
Pediatrics. 2008;122:1332- 1342.
16. Lobo C, Hankins JS, Moura P, Pinto JC. Hydroxyurea therapy reduces
mortality among children with sickle cell disease. Blood.
2010;116:843-843.
17. US Department of health and human services. Evidenced- based
management of sickle cell disease: Expert Panel Report, 2014.
https://www.nhlbi.nih.gov/guidelines.
18. Mulumba LL, Wilson L. Sickle cell disease among children in Africa:
an integrative literature review and global recommendations. Int J
Africa Nurs Sci. 2015;3:56-64.
19. Adewoyin AS, Oghuvwu OS, Awodu OA. Hydroxyurea therapy in adult
Nigerian sickle cell disease: a monocentric survey on pattern of use,
clinical effects and patient’s compliance. Afr Health Sci.
2017;17:255-261.
20. Akinyanju OO. A Profile of sickle cell disease in Nigeria. Ann N Y
Acad Sci. 1989;565:126-136.
21. Galadanci N, Wudil BJ, Balogun TM, et al. Current sickle cell
disease management practices in Nigeria. Int Health. 2014;6:23-28.
22. Ojewunmi OO, Adeyemo TA, Ayinde OC, Iwalokun B, Adekile A. Current
perspectives of sickle cell disease in Nigeria: changing the narratives.
Expert Rev Hematol. 2019;12:609-620.
23. Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for
children with sickle cell anemia in sub-Saharan Africa. N Engl J Med.
2018;380:121-131.
24. Adeyemo TA, Diaku-Akinwunmi IN, Ojewunmi OO, Bolarinwa AB, Adekile
AD. Barriers to the use of hydroxyurea in the management of sickle cell
disease in Nigeria. Hemoglobin. 2019;43:188-192.
25. Opoka R, Ndugwa C, Latham TS, et al. Novel use Of Hydroxyurea in an
African Region with Malaria (NOHARM): a trial for children with sickle
cell anemia. 2017;130:2585-2593.
26. Akinsete A. Experience with hydroxy carbamide use; indications,
adverse effects and clinical course at a tertiary are hospital in Lagos.
Nig Qrtly J Hosp Med 2019;28:26-30.
27. Ofakunrin AOD, Adekola KU, Oguche S, Okpe ES, Sagay AS. Efficacy and
safety of hydroxyurea in the treatment of sickle cell anemia children in
Jos, North Central Nigeria. J Trop Pediatr. 2019;66:290-298.
28. Lagunju, I, Brown , BJ, and Sodeinde O. HydroxyUrea lowers
transcranial doppler flow velocities in children with sickle cell anemia
in a Nigerian cohort. Pediatr Blood Cancer. 2015;62:1587-1591.
29. Lagunju, IO, Brown , BJ, Oyinlade A. Annual stroke incidence in
Nigerian with sickle cell disease and elevated TCD velocities treated
with hydroxyurea. Pediatr Blood Cancer. 2019;66:27252.
30. Ofakunrin AOD, Adekola K, Okpe ES, et al. Level of utilization and
provider-related barriers to hydroxyurea use in the treatment of sickle
cell disease in Jos, Nigeria.Blood. 2019;134:1029.
31. Aliyu ZY, Babadoko A, Mamman A. Hydroxyurea utilization in Nigeria,
a lesson in Public health. Blood. 2007;110:80.
32. Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with
lower costs of care of young children with sickle cell anemia.
Pediatrics. 2013;132:677-683.
33. Freampong KO. Sickle Pan-African Research Consortium(SPARCO):
Hydroxyurea SOP; 2019.
34. Luzzatto L, Makani J. Hydroxyurea - An essential medicine for sickle
cell disease in Africa. N Engl J Med. 2019;380:187-189.
35. Jain DL, Apte M, Colah R, et al. Efficacy of fixed low dose
hydroxyurea in Indian children with sickle cell anemia: a single centre
experience. Indian Pediatr 2013;50:929-933.
36. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal
hemoglobin necessary for treatment of sickle cell disease. N Engl J Med.
1988;318:96-99.
37. Ware RE. Hydroxycarbamide: clinical aspects. C R Biol.
2013;336:177-182.
38. Adekile AD et al. Hemoglobin F in sickle cell anemia. Birkhauser
Verlag. 1993;49:0016- 0027.
39. Park H, Bhatti S, Chakravorty S. Effectiveness of hydroxycarbamide
in children with sickle cell disease – Analysis of dose-response
metrics in a large birth cohort in a tertiary sickle cell centre.
Pediatr Blood Cancer. 2019;66:27615.
40. Chambers TM, Kahan S, Camanda JF, Scheurer M, Airewele GE.
Intermittent or uneven daily administration of low-dose hydroxyurea is
effective in treating children with sickle cell anemia in Angola.
Pediatr Blood Cancer. 2018;65:27365.
41. Inusa BPD, Wale A, Hassan AA et al. Low-dose hydroxycarbamide
therapy may offer similar benefit as maximum tolerated dose for children
and young adults with sickle cell disease in low-middle-income
settings.2018;7:1-9.
42. Akingbola TS, Tayo B, Saraf SL, et al. Low fixed dose hydroxyurea
for the treatment of adults with sickle cell disease in Nigeria. Blood.
2017;130:981.